Hanx Biopharmaceuticals Presents Four Innovative Cancer Therapies at 2026 AACR Annual Meeting
核心洞察
Hanx Biopharmaceuticals (搜索) showcased four innovative drug research achievements at the 2026 AACR Annual Meeting, demonstrating the company's robust R&D capabilities in oncology therapeutics.
HX044, a first-in-class CTLA-4 (搜索)/SIRP𝛼 (搜索) bifunctional fusion protein, showed 4x improved efficacy compared to ipilimumab with minimal increase in immune-related adverse events in preclinical studies.
The company presented two novel antibody-drug conjugates, HX116 (搜索) and HX112 (搜索), targeting PD-L1 (搜索) and VEGF (搜索) pathways with superior anti-tumor activity compared to existing therapies.
Hanx Biopharmaceuticals (搜索) (Stock Code: 3378) announced four innovative drug research achievements presented in poster format at the 2026 American Association for Cancer (搜索) Research (AACR) Annual Meeting, held April 17-22 at the San Diego Convention Center in California. The presentations highlight the company's advancing pipeline of next-generation immunotherapies and antibody-drug conjugates targeting solid tumors (搜索) with significant unmet medical needs.
HX044: Next-Generation CTLA-4 Targeted Therapy
HX044 represents a globally innovative CTLA-4 (搜索)/SIRP𝛼 (搜索) bifunctional fusion protein designed as the next generation of CTLA-4 targeted therapies. The drug simultaneously targets CTLA-4 and CD47 (搜索), enhancing the removal of regulatory T-cells within the tumor microenvironment to reduce tumor-induced immunosuppression and amplify anti-tumor activity.
Preclinical data demonstrated preferential targeting of tumor-infiltrating regulatory T-cells (TIL-Treg), which express higher levels of CTLA4. The therapy showed a widened therapeutic window compared to ipilimumab, with approximately 4x improved efficacy at lower doses and minimal increase in immune-related adverse events. HX044 is currently in Phase I clinical development, with primary development focus on PD-1 (搜索)/ICI-resistant solid tumors (搜索).
Bispecific ADC Platform: HX116 and HX112
HX116 (搜索) is a potentially first-in-class bispecific antibody-drug conjugate (BsAbADC) independently developed by the company. It targets PD-(L)1 and VEGF (搜索) while introducing additional mechanisms of action, including direct cytotoxicity and enhanced immunogenic cell death-mediated anti-tumor immunity. In preclinical studies, HX116 demonstrated superior activity compared to its parent BsAb and showed efficient internalization in PD-L1 (搜索)+ cells, especially in the presence of VEGF.
The drug exhibited comparable cytotoxicity to SGN-PDL1V, the current clinical lead, with indications of more specific tumor targeting and potentially reduced off-tumor toxicity. HX116 (搜索) combines direct tumor-cell killing with enhanced anti-tumor immunity via immunogenic cell death.
HX112 (搜索) is a novel PD-L1 (搜索)-targeted antibody-drug conjugate independently developed for the treatment of various solid tumors (搜索). The drug demonstrated similar or superior tumor specificity compared to SGN-PDL1V in 3D organoid models and showed potential to avoid the use of tumor microenvironment-cleavable linkers, which could reduce off-target toxicity and side effects.
3D Tumor Organoid Evaluation System
The company presented an innovative ADC preclinical evaluation system using 3D tumor organoids. The study verified that 3D tumor organoids are better predictors of in vivo anti-tumor drug effects compared to traditional 2D cell cultures. Significant differences in internalization and cytotoxicity of ADCs, depending on the antibody epitope, were observed in 3D versus 2D systems.
This innovation enhances drug development efficiency and could accelerate the path to market for the company's pipeline candidates by providing more accurate predictions of clinical outcomes and supporting a streamlined preclinical candidate assessment process.
Clinical and Commercial Implications
The research achievements position Hanx Biopharmaceuticals (搜索) as a potential leader in the oncology sector, with each program targeting large, underserved markets in solid tumor oncology. HX044's advancement into Phase I clinical trials and promising preclinical results for HX116 (搜索) and HX112 (搜索) could lead to significant value inflection points as data matures.
Founded in 2014, Hanx Biopharmaceuticals (搜索) focuses on structural biology, translational medicine, and clinical development, aiming to deliver affordable, safe, and effective therapies for cancer (搜索) and autoimmune diseases globally. The company specifically notes that these products are still under development and may not ultimately be successfully marketed.